Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQSU3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,951
Award facts
- Contract value 100% obligated
- $18,950.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,950.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The contract was executed on December 1, 2025, with an ultimate completion date of December 22, 2025, and carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations globally under the PPV-G GEN V program, a $30.3 billion acquisition strategy designed to provide recurring medical supply needs to military healthcare facilities. The company's established performance across a diverse portfolio including specialty pharmaceuticals, biologics, vaccines, and medical consumables demonstrates its capability to meet the specialized requirements of the federal military medical system. XOLAIR (omalizumab), an immunosuppressant biologic agent used to treat allergic conditions and severe asthma, represents one of the company's specialty pharmaceutical offerings supplied through this strategic prime vendor arrangement.
Quick answers
Who was awarded contract SPE2DR26FQSU3?
SPE2DR26FQSU3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FQSU3 worth?
The government has obligated $18,951 on SPE2DR26FQSU3.
Is contract SPE2DR26FQSU3 an order under another contract?
Yes. SPE2DR26FQSU3 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSU3 competed?
The extent of competition for SPE2DR26FQSU3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award